Flow cytometry‐based monitoring of chimeric antigen receptor ( <scp>CAR</scp> ) T cells: Reagent selection, assay design, and clinical utility
Accurate quantification of chimeric antigen receptor (CAR) T cells is essential for monitoring post-infusion CART expansion and persistence and for real-time clinical decision-making. Multiparameter flow cytometry (MFC) enables rapid, live-cell detection with absolute quantification and concurrent immunophenotypic characterization. This review focuses on the practical and technical aspects of flow cytometry-based CAR T-cell monitoring, including selection of CAR detection reagents (target-specific, construct-specific, and target-agnostic strategies), assay optimization, purpose-driven panel design, and matrix-appropriate validation for peripheral blood and other clinically relevant specimens. We also address assay considerations unique to gene-edited allogeneic CAR T-cell products, including the use of surrogate immunophenotypic approaches when construct-specific reagents are unavailable. Finally, we discuss the role of MFC in identifying CAR T-cell clonal expansions and in evaluating suspected secondary hematolymphoid neoplasms in the post-CAR T setting.
Authors
- Jianhua Ling
- Wei J. Wang (ORCID: https://orcid.org/0000-0002-4848-7394)
- Sa A. Wang
Institutions
- The University of Texas MD Anderson Cancer Center (US)
Publication Details
- Journal
- Cytometry Part B Clinical Cytometry
- Published
- 2026-03-23
- DOI
- https://doi.org/10.1002/cyto.b.70026
- Primary Topic
- CAR-T cell therapy research
- Type
- article
- Field-Weighted Citation Impact
- 0.00